{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:19:15Z","timestamp":1787779155428,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbrc.2025.152001","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:03:25Z","timestamp":1747163005000},"page":"152001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Elucidating the anticancer properties of posaconazole in triple-negative breast cancer through in-silico and in-vitro analysis"],"prefix":"10.1016","volume":"771","author":[{"given":"Lakshi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujisha S.","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arupam","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvinder Kaur","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbrc.2025.152001_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ajco.12661","article-title":"Epidemiology of breast cancer in Indian women: breast cancer epidemiology","volume":"13","author":"Malvia","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bbrc.2025.152001_bib2","doi-asserted-by":"crossref","first-page":"22218","DOI":"10.18632\/oncotarget.14731","article-title":"Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies","volume":"8","author":"Ocana","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.bbrc.2025.152001_bib3","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1111\/bph.13211","article-title":"Therapeutic targets of triple\u2010negative breast cancer: a review","volume":"172","author":"Jamdade","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152001_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"30","key":"10.1016\/j.bbrc.2025.152001_bib5","doi-asserted-by":"crossref","first-page":"29347","DOI":"10.18632\/oncotarget.5119","article-title":"A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation","volume":"6","author":"Artemov","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bbrc.2025.152001_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/md16080279","article-title":"Current screening methodologies in drug discovery for selected human diseases","volume":"16","author":"Lage","year":"2018","journal-title":"Mar. Drugs"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152001_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152001_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1039\/C5NP00005J","article-title":"Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products","volume":"32","author":"Kibble","year":"2015","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.bbrc.2025.152001_bib9","series-title":"Innovative Approaches in Drug Discovery","first-page":"127","article-title":"Network pharmacology","author":"Chandran","year":"2017"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152001_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1130-1406(07)70047-5","article-title":"Farmacolog\u00eda de los azoles","volume":"24","author":"Ram\u00f3n Azanza","year":"2007","journal-title":"Rev. Iberoam. Micol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152001_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.152001_bib12","article-title":"Posaconazole inhibits the stemness of cancer stem-like cells by inducing autophagy and suppressing the Wnt\/\u03b2-catenin\/survivin signaling pathway in glioblastoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152001_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1535-7163.MCT-15-0729-T","article-title":"Posaconazole, a second-generation triazole antifungal drug, inhibits the hedgehog signaling pathway and progression of basal cell carcinoma","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152001_bib14","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3390\/cancers12102853","article-title":"Profiling anti-apoptotic BCL-xL protein expression in glioblastoma tumorspheres","volume":"12","author":"Fanfone","year":"2020","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.bbrc.2025.152001_bib15","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.7150\/thno.60503","article-title":"BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators","volume":"11","author":"Castellanet","year":"2021","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.bbrc.2025.152001_bib16","article-title":"Aurora kinase A and Bcl-xL inhibition suppresses metastasis in triple-negative breast cancer","volume":"23","author":"Skov","year":"2022","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152001_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"23","key":"10.1016\/j.bbrc.2025.152001_bib18","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.3390\/cancers13235970","article-title":"RAP1\/TERF2IP\u2014A multifunctional player in cancer development","volume":"13","author":"Deregowska","year":"2021","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.bbrc.2025.152001_bib19","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2025.152001_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152001_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbrc.2025.152001_bib22","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1080\/07391102.2023.2220036","article-title":"Molecular modelling, docking and network analysis of phytochemicals from haritaki churna: role of protein cross-talks for their action","volume":"42","author":"Khan","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152001_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12929-023-00986-4","article-title":"SCEL regulates switches between pro-survival and apoptosis of the TNF-\u03b1\/TNFR1\/NF-\u03baB\/c-FLIP axis to control lung colonization of triple negative breast cancer","volume":"30","author":"Chan","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.bbrc.2025.152001_bib24","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1940-6207.CAPR-22-0106","article-title":"Targeting the mTOR pathway for the prevention of ER-Negative breast cancer","volume":"15","author":"Mazumdar","year":"2022","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152001_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5603\/FHC.a2021.0029","article-title":"Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6\/MAPK signaling","volume":"59","author":"Huang","year":"2021","journal-title":"Folia Histochem. Cytobiol."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152001_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1535-7163.MCT-21-1044","article-title":"Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB- and TFE3-Mediated lysosome biogenesis and autophagy","volume":"21","author":"Soleimani","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152001_bib27","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152001_bib28","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152001_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152001_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188068","article-title":"Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma","volume":"12","author":"Ortiz","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152001_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1747-1028-4-13","article-title":"Regulation of DNA replication by the S-phase DNA damage checkpoint","volume":"4","author":"Willis","year":"2009","journal-title":"Cell Div."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25007156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25007156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:37:21Z","timestamp":1787776641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25007156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"alternative-id":["S0006291X25007156"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152001","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elucidating the anticancer properties of posaconazole in triple-negative breast cancer through in-silico and in-vitro analysis","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152001"}}